• NEWS & PRESS
  • pressReleases
  • newsMedia
  • CAREERS
  • Career Openings
  • CONTACT US
  • Science

    Pipeline
    Program
    Target
    Indication
    Mono/Combo
    Discovery
    IND Enabling
    Phase I/Ia
    POC
    Pivotal
    Rights
    Partner
    Precision Oncology
    ABSK011*
    FGFR4
    FGF19+ HCC
    Monotherapy
    Global
    ABSK011*
    FGFR4
    FGF19+ HCC
    Combination
    therapy(ⅱ)
    Global
    ABSK012
    FGFR4 Mutant
    RMS and other
    solid tumors
    Monotherapy
    Global
    ABSK091*
    pan-FGFR
    FGFRalt UC
    Monotherapy
    global
    Global
    AstraZeneca
    ABSK091*
    pan-FGFR
    FGFRalt UC
    Combination therapy
    Global
    AstraZeneca
    ABSK091*
    pan-FGFR
    FGFRalt GC
    Monotherapy/ Combination therapy
    global
    Global
    AstraZeneca
    ABSK091*
    pan-FGFR
    Other solid tumors
    Monotherapy/ Combination therapy
    Global
    AstraZeneca
    ABSK061
    FGFR2/3
    Solid tumors
    Monotherapy
    Global
    ABSK121
    pan-FGFR Mutant
    Solid tumors
    Monotherapy
    Global
    ABSK071
    KRAS
    Solid tumors
    Monotherapy
    Global
    ABSK111
    EGFR Exon20
    NSCLC
    Monotherapy
    Global
    ABSK131
    Undisclosed
    Multiple tumors
    Monotherapy
    Global
    ABSK141
    Undisclosed
    Multiple tumors
    Monotherapy
    Global
    Immuno-Oncology
    ABSK021
    CSF-1R
    TGCT, solid tumors
    Monotherapy
    Global
    ABSK021
    CSF-1R
    Solid tumors
    Combination therapy
    Global
    ABSK021
    CSF-1R
    cGvHD
    Monotherapy
    Global
    ABSK021
    CSF-1R
    ALS
    Monotherapy
    Global
    ABSK081
    CXCR4
    TNBC
    Combination therapy(ⅲ)
    Greater China
    X4
    ABSK081
    CXCR4
    Other solid tumors
    Combination therapy
    Greater China
    X4
    ABSK081
    CXCR4
    WHIM
    Monotherapy
    global
    Greater China
    X4
    ABSK043
    PD-L1
    Multiple tumors
    Monotherapy
    Global
    ABSK051
    CD73
    Multiple tumors
    Monotherapy
    Global
    ABSK031
    RORγt
    Multiple tumors
    Monotherapy
    Global

    Tel:(+86) 021-68912098

    E-Mail:Public@abbisko.com Bd@abbisko.com

    Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1